AcelRx receives positive CHMP opinion for DZUVEO(TM) for management of acute moderate to severe pain in medically monitored settings

DZUVEO is AcelRx's second developed sublingual sufentanil-based product to receive positive CHMP opinion, with Zalviso® already approved Resubmission of New Drug Application for DSUVIA™ (known as DZUVEO in Europe) to the FDA in the U.S. is planned f... Biopharmaceutical, Drug Delivery, Regulatory AcelRx Pharmaceuticals, DZUVEO, DSUVIA, sufentanil, sublingual
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news